PMV Pharmaceuticals upgraded by Oppenheimer with a new price target
$PMVP
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $6.00 | Perform → Outperform | Oppenheimer |
| 5/13/2024 | $6.00 | Buy | Craig Hallum |
| 4/12/2024 | $5.00 | Buy | Jefferies |
| 12/27/2023 | $7.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $30.00 | Perform → Outperform | Oppenheimer |
| 3/2/2022 | Perform → Outperform | Oppenheimer | |
| 9/22/2021 | $35.00 → $43.00 | Neutral → Buy | Goldman Sachs |
| 8/19/2021 | Perform | Oppenheimer |
DEFA14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
DEF 14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
S-8 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00
Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00
PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumorsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $112.9 million as of December 31, 2025 providing
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM). The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients. The study published in NEJM entitled, "Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y2
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in
Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr
SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)